— PUBLICATIONS —

Liste des publications GINECO - Cancer Ovaire 2018


 

  • SOLO1 – Article (The New England Journal of Medicine)
    K. Moore
    Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    The New England Journal of Medicine - Octobre 2018 (réf. PubMed : PMID: 30345884 - DOI: 10.1056/NEJMoa1810858)
  • SOLO 2 – Article (Lancet Oncology)
    M. Friedlander
    Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
    Lancet Oncology - Août 2018 (réf. PubMed : PMID: 30026002 - DOI: 10.1016/S1470-2045(18)30343-7)
  • EXPRESSION IV – Article (Bulletin du cancer)
    M. Lorcet
    [Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].
    Bulletin du cancer - Août 2018 (réf. PubMed : PMID: 29544693 - DOI: 10.1016/j.bulcan.2018.01.015)
  • AGO-OVAR 16 – Article (Annals of Oncology)
    M. Friedlander
    Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.
    Annals of Oncology - Mars 2018 (réf. PubMed : PMID: 29267856 - DOI: 10.1093/annonc/mdx796)
  • TMRG – Article (Bulletin du cancer)
    C. Rousset-Jablonski
    [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].
    Bulletin du cancer - Mars 2018 (réf. PubMed : PMID: 29397916 - DOI: 10.1016/j.bulcan.2017.10.032)
Haut de page

Modifié le 24-07-2019 10:07